Bill · H.R. 8000· House(119-HR-8000)
END 7-OH Act
- Introduced
- 3/19/2026
- Last activity
- 3/19/2026 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Sponsored by
- Gus Bilirakis
- Cosponsors
- - 9 - 0
- Introduced
- In Committee
What this bill would do
This bill is known as the End Needless Distribution of 7-OH Act or the END 7-OH Act. It was introduced in the House of Representatives on March 19, 2026, by Mr. Bilirakis. The legislation amends the Controlled Substances Act. Its main purpose is to add synthetic 7-hydroxymitragynine to the list of Schedule I controlled substances. However, the bill explicitly states that it does not include 7-hydroxymitragynine naturally contained in the plant known as kratom.
Yes
Does this give people more protection from unfair business practices?+5
The regulation of synthetic substances may increase consumer safety and oversight.
Does this do more about addiction and overdose deaths?+4
By scheduling synthetic 7-hydroxymitragynine, the bill may assist in curbing the distribution of potent synthetic substances.
Does this give the federal government more power?+3
The bill expands federal control by adding a substance to the Controlled Substances Act.
The opposite
Would business owners be better off under this?-2
The scheduling may create new regulatory burdens for manufacturers of synthetic substances.
Who it would affect, and how
Potential Positive Impacts for People
- Exemption for Natural Plant Material: Section 2 of the bill specifies that the scheduling restriction does not apply to 7-hydroxymitragynine naturally contained in the plant Mitragyna speciosa Korth, also known as kratom. This is a positive outcome because it protects the natural form of the substance from being classified under Schedule I.
Potential Negative Impacts for People
- Strict Scheduling for Synthetics: Section 2 of the bill places synthetic equivalents of 7-hydroxymitragynine into Schedule I of the Controlled Substances Act. This could be viewed as a negative outcome or burden by individuals or groups who utilize or manufacture these synthetic equivalents, as Schedule I substances are heavily restricted.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Economy And Finance
- Improves Consumer Protection+5
- Healthcare
- Improves Opioid Crisis Response+4
- Governance And Ideology
- Increases Federal Power+3
- Demographic And Interest Groups
- Good For Business Owners-2
- 9/28/2026
- 1 Cosponsor added.
- 9/16/2026
- 5 Cosponsors added.
- 8/13/2026
- 1 Cosponsor added.
- 3/25/2026
- 1 Cosponsor added.
- 3/20/2026
- 1 Cosponsor added.
- 3/19/2026
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House
Stephanie BiceRepublican · Oklahoma
Vern BuchananRepublican · Florida
Lance GoodenRepublican · Texas
Mike HaridopolosRepublican · Florida
Mike KellyRepublican · Pennsylvania
Darin LaHoodRepublican · Illinois
Laurel LeeRepublican · Florida
Richard McCormickRepublican · Georgia
Mark MessmerRepublican · Indiana